

## United States Lent and Trademark Office



UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. (2023)
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO
09/583,599	05/31/2000	Qing Min Wang	99A209	4043
20411 7	7590 01/10/2003			
THE BOC GROUP INC			EXAMINER	
100 MOUNTAIN AVENUE MURRAY HILL			TRAN, THAO T	
NEW PROVIDENCE, NJ 07974-2064			ART UNIT	PAPER NUMBER
			1711	14
			DATE MAILED: 01/10/2003	

Please find below and/or attached an Office communication concerning this application or proceeding.

•			
		Application No.	Applicant(s)
	•	09/583 599	WANG ET AL
Office Action Summary		Examiner	Art Unit
		Thao T Tran	1711
The Period for Rep	MAILING DATE of this communication app ly	ears on the cover s	heet with the correspondence address
THE MAILIN - Extensions of after SIX (6) N - If the period f - If NO period f - Failure to rep - Any reply rece	NED STATUTORY PERIOD FOR REPLY NG DATE OF THIS COMMUNICATION. Itime may be available under the provisions of 37 CFR 1.13 MONTHS from the mailing date of this communication or reply specified above is less than thirty (30) days, a reply or reply is specified above, the maximum statutory period very within the set or extended period for reply will, by statute, exived by the Office later than three months after the mailing term adjustment. See 37 CFR 1.704(b).	36(a) In no event, however y within the statutory minim will apply and will expire SI , cause the application to b	er, may a reply be timely filed  rum of thirty (30) days will be considered timely  X (6) MONTHS from the mailing date of this communication  ecome ABANDONED (35 U.S.C. § 133).
1)⊠ Res	consive to communication(s) filed on 23 C	October 2002	
2a) This	action is <b>FINAL</b> . 2b)⊠ Th	is action is non-fina	al.
close	ed in accordance with the practice under	ance except for for Ex parte Quayle, 1	mal matters, prosecution as to the merits is 935 C.D. 11, 453 O.G. 213.
Disposition of		10 E1 E2 and E4 E4	ic/are pending in the application
	n(s) <u>1-8,11,13,14,16-25,28,30,31,33-46,4</u>		
_ ′	f the above claim(s) is/are withdraw	wn from considerat	1011.
·	n(s) is/are allowed.		
•	n(s) is/are rejected.		
·	n(s) is/are objected to.	40 40 54 50 54 6	4 subject to section and/as alaction
8) Claim requirement.	i(s) <u>1-8, 11, 13-14, 16-25, 28, 30-31, 33-4</u>	10, 49, 51-52, 54-0	4 are subject to restriction and/or election
Application Pa	pers		
9)∏ The sr	pecification is objected to by the Examine	r.	
10)∏ The dr	awing(s) filed on is/are: a)□ accep	oted or b) objected	to by the Examiner.
Appl	icant may not request that any objection to the	e drawing(s) be held	in abeyance See 37 CFR 1 85(a)
11) The pr	roposed drawing correction filed on	_ is: a)□ approved	b) disapproved by the Examiner
If ap	proved, corrected drawings are required in rep	oly to this Office actio	on
12)∏ The oa	ath or declaration is objected to by the Ex	aminer.	
Priority under	35 U.S.C. §§ 119 and 120		
13) Ackno	owledgment is made of a claim for foreign	n priority under 35 l	U.S.C. § 119(a)-(d) or (f).
a)∏ AⅡ	b) Some * c) None of:		
1.	Certified copies of the priority documents	s have been receiv	ved.
2.	Certified copies of the priority documents	s have been receiv	red in Application No
	Copies of the certified copies of the prior application from the International Bu e attached detailed Office action for a list	reau (PCT Rule 17	'.2(a)).
			U.S.C. § 119(e) (to a provisional application).
a) 🗌 T	the translation of the foreign language prowledgment is made of a claim for domesti	ovisional application	n has been received.
Attachment(s)		, ,	
1) Notice of Re 2) Notice of Dra	ferences Cited (PTO-892) aftsperson's Patent Drawing Review (PTO-948) Disclosure Statement(s) (PTO-1449) Paper No(s)	5) 🔲 1	nterview Summary (PTO-413) Paper No(s) Notice of Informal Patent Application (PTO-152) Other
S. Patent and Trademark			<del></del>

Art Unit: 1711

## **DETAILED ACTION**

## Election/Restrictions

- 1. This application contains claims directed to the following patentably distinct species of the claimed invention:
- (A) claims 1-8, 11, 16-25, 28, 33-46, 49, and 54-64; including a leveler compound that is a polymeric compound; and
- (B) claims 13-14, 30-31, and 51-52; including a leveler compound that is a low molecular weight compound.

Applicant is required under 35 U.S.C. 121 to elect a single disclosed species for prosecution on the merits to which the claims shall be restricted if no generic claim is finally held to be allowable.

Applicant is advised that a reply to this requirement must include an identification of the species that is elected consonant with this requirement, and a listing of all claims readable thereon, including any claims subsequently added. An argument that a claim is allowable or that all claims are generic is considered nonresponsive unless accompanied by an election.

Upon the allowance of a generic claim, applicant will be entitled to consideration of claims to additional species which are written in dependent form or otherwise include all the limitations of an allowed generic claim as provided by 37 CFR 1.141. If claims are added after the election, applicant must indicate which are readable upon the elected species. MPEP § 809.02(a).

Art Unit: 1711

Should applicant traverse on the ground that the species are not patentably distinct. applicant should submit evidence or identify such evidence now of record showing the species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C. 103(a) of the other invention.

- 2A. Should (A) be selected, a plurality of disclosed patentable distinct species of a polymeric leveler compound is set forth, comprising:
  - 1) polyethylenimine, 80% ethoxylated;
  - 2) poly(allylamine);
  - 3) poly(allylamine hydrochloride);
  - 4) polyaniline, sulfonated, 5 wt. % in water, 75 mole % sulfonated;
  - 5) poly[bis((2-chloroethyl)etheralt-1,3-bis[3-(dimethylamino)propyl]urea, quaternited;
- 6) poly[N,N'-bis(2,2,6,6-tetramethyl-4-piperidinyl)-1.6-hexanediamine-co-2.4-dichloro-6-morpholino-1,3,5-triazine;
  - 7) polyacrylamide;
  - 8) poly(acrylamide-co-diallyldimethylammonium chloride);
  - 9) poly(diallydimethylammonium chloride);
  - 10) poly(melamine-co-formaldehyde), partially methylated;
  - 11) poly(4-cinylpyridine). 25% cross-linked; and
  - 12) poly(1,2-dihydro-2,2,4-trimethylquinoline).
- 2B. Should (B) be selected, a plurality of disclosed patentable distinct species of a low molecular weight leveler compound is set forth, comprising:

Art Unit: 1711

- 1) 2,5-dithiobiurea.
- 2) dithiooxamide:
- 3) 1-phenyl-2-thiourea;
- 4) diethylenetriamine,
- 5) p-xylenebis(tetrahydrothiophenium)chloride;
- 6) [2-thiohydantoin,] pseudo thiohydantoin,
- 7) R-(-)-thiazolidine-4-carboxylic acid.
- 8) 3-(2'-thiopyridinium) propyl sulfonate:
- 9) 2,2'-dipyridyl disulfide;
- 10) 4,4'-dipyridyl disulfide;
- 11) thionicotinamide;
- 12) 4-(trifluoromethyl)-2-pyrimidinethiol;
- 13) 2-mercapto-4-methylpyrimidine hydrochloride;
- 14) 5-phenyl-1 H-1,2,4-triazole-3-thiol;
- 15) 5-(4'-pyridyl)-1 H-1,2,4-triazole-3-thiol;
- 16) 2-amino-6-purinethiol;
- 17) 4-amino-5-(4'-pyridyl)-4 H-1,2.4-triazole-3-diol:
- 18) diethyl heptadedecyl imidazolinium ethylsulfate;
- 19) hexamethylenetetraamine;
- 20) 1,3-bis(3-pyridylmethyl)-2-thiourea;
- 21) 2,4-diamino-6-mercaptopyrimidine hemisulfate;
- 22) dithiouracil;

Art Unit: 1711

- 23) 4,5-diamino-2,6-dimercaptopyrimidine;
- 24) 4,5-diamino-6-hydroxy-2-marcaptopyrimidine hemisulfate hydrate:
- 25) 4(5)-imidazoledithio-carboxylic acid;
- 26) 2-mercapto-5-benzimidazolesulfonic acid;
- 27) sodium salt dihydrate;
- 28) 2-thiouracil;
- 29) trithiocyanuric acid;
- 30) (2-pyrimidylthio) acetic acid;
- 31) 7-trifluoromethyl-4-quinlinethiol;
- 32) 5-carbethoxy-2-thiouracil;
- 33) 1 H-1,2,4-triazole-3-thiol;
- 34) 1-phenyl-1 H-1,2,4-triazole-5-thiol;
- 35) N,N'-ethylene thiourea; and
- 36) 2-mercapto benzothiazole.
- 3. Applicant is required under 35 U.S.C. 121 to elect a single disclosed species, even though this requirement is traversed.
- 4. Should applicant traverse on the ground that the species are not patentably distinct applicant should submit evidence or identify such evidence now of record showing the species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C. 103(a) of the other invention.

Art Unit: 1711

5. A telephone call was made to Wan Yee Chung on January 6. 2003 to request an oral election to the above restriction requirement, but did not result in an election being made

Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

- 6. Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).
- 7. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Thao T. Tran whose telephone number is 703-306-5698. The examiner can normally be reached on Monday-Friday, from 8:30 a.m. 5:00 p.m.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, James Seidleck can be reached on 703-308-2462. The fax phone numbers for the organization where this application or proceeding is assigned are 703-872-9310 for regular communications and 703-872-9311 for After Final communications

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is 703-308-0661

tt

tt

January 7, 2003

Gemes J. Seidleck Supercoory Patent Examiner